BioSpace

MAY 5, 2021

We interviewed Krissy Fuller, a human resources consultant, to learn more about the issue of mandated vaccines from an HR perspective and shared her predictions on what changes she thinks will last after the pandemic.

Vaccination 85

Vaccination Vaccine HR 85

Pharmaceutical Technology

JUNE 13, 2023

The combination therapy is intended to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in adult patients, after recurrence or progression on or after an endocrine-based regimen.

Hormones 245

Hormones Protein Trials Drugs 245

Pharmaceutical Technology

NOVEMBER 17, 2023

Truqap is approved in combination with Faslodex for HR-positive/HER2-negative breast cancer patients in the US.

FDA Approval 130

FDA Approval HR 130

Pharmaceutical Technology

JANUARY 13, 2023

The regulatory approval was based on the data obtained from the DESTINY-Breast04 Phase III trial, which was conducted in HR-positive or HR-negative, HER2-low unresectable or metastatic breast cancer patients, who have received one or two prior lines of chemotherapy.

Clinical Trials 321

Clinical Trials Clinical Trials Antibody Trials 321

Medical Xpress

DECEMBER 6, 2022

Among premenopausal women with hormone receptor (HR)-positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on a genomic assay called Breast Cancer Index (BCI) had increased risk of distant recurrence, and those with low BCI benefited more from the addition of ovarian suppression therapy to endocrine therapy after 12 (..)

Genome 63

Genome Genomics HR Hormones 63

BioTech 365

NOVEMBER 16, 2020

Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services CALGARY, Alberta–(BUSINESS WIRE)–#albertadentist–With businesses everywhere struggling to keep their doors … Continue reading (..)

HR 40

HR 40

BioSpace

NOVEMBER 16, 2023

The company's Truqap, in combination with its endocrine therapy Faslodex, has been approved by the regulator for adult patients with advanced HR-positive breast cancer with specific biomarker alterations.

FDA Approval 116

FDA Approval HR Regulation 116

Pharmaceutical Technology

JANUARY 27, 2023

Daiichi Sankyo president and CEO and Oncology Business global head Ken Keller said: “The approval of Enhertu in HER2 low metastatic breast cancer represents a significant clinical advance for patients in Europe with both HR-positive and HR-negative disease who previously have had limited treatment options in the late-line setting.

Antibody 235

Antibody HR Medicine Drugs 235

Pharmaceutical Technology

SEPTEMBER 13, 2022

Hormone receptor-positive/human epidermal growth factor negative (HR+/HER2-) breast cancer accounts for approximately 70% of all breast cancers, with close to 40,000 new cases diagnosed each year worldwide. Findings of the study, reported at the ESMO Congress 2022, demonstrated a 3.2-month months) versus physicians’ choice chemotherapy (11.2

Marketing 162

Marketing FDA Approval HR Hormones 162

Pharmaceutical Technology

JUNE 2, 2023

Data from Novartis ’ Phase III NATALEE trial show that adding Kisqali to endocrine therapy lowered the risk of cancer recurrence by 25% in patients with hormone receptor-positive (HR+)/HER2- early-stage breast cancer (EBC).

Hormones 130

Hormones Trials HR Drugs 130

The Pharma Data

MARCH 7, 2022

Nasdaq: GILD) today announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy ® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. Gilead Sciences, Inc.

HR 52

HR Hormones Medicine Clinical Trials 52

BioTech 365

SEPTEMBER 19, 2021

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer With the MONALEESA-2 final analysis, only … Continue reading →

HR 52

HR 52

Pharmaceutical Technology

AUGUST 8, 2022

According to the trial data, Enhertu lowered disease progression or mortality risk by 50% compared with chemotherapy according to the physician’s choice in HER2-low metastatic breast cancer patients with hormone receptor (HR)-positive disease or HR-negative disease. months compared with 5.1 months for the chemotherapy arm.

FDA Approval 264

FDA Approval Clinical Trials Clinical Trials Hormones 264

Pharmaceutical Technology

JULY 28, 2023

Gilead Sciences has received approval from EC for Trodelvy, for pre-treated HR-positive, HER2-negative metastatic breast cancer.

Drugs 130

Drugs HR 130

Pharmaceutical Technology

JUNE 9, 2023

The subunit antigen in the vaccine has been based on the structure of the targeting S-RBD and HR proteins of the XBB and BA.5 WestVac Biopharma and its subsidiary WestVac Biopharma (Guangzhou) constructed the vector for the coviccine vaccine using the fast response of the insect cell expression platform. 5 subvariants.

Vaccination 269

Vaccination Vaccine Protein Antibody 269

Pharmaceutical Technology

JULY 1, 2022

The latest filing is based on non-clinical and clinical data for Paxlovid and also comprised data from the Phase II/III EPIC-HR clinical trial. Paxlovid received emergency use authorization to treat mild-to-moderate Covid-19 in adults and paediatric patients aged 12 years and above who are at increased disease progression risk.

Clinical Trials 264

Clinical Trials Clinical Trials Clinical Development Vaccination 264

Pharmaceutical Technology

JULY 8, 2022

The company claimed that the utmost benefit is reported in hormone-receptor positive (HR+) women and those who commence treatment with Nerlynx within a year of receiving trastuzumab-based therapy. In a Phase III ExteNET clinical trial, neratinib offered a 34% decline in the risk of recurrence and a 2.3%

FDA Approval 246

FDA Approval Drugs Clinical Trials Clinical Trials 246

BioTech 365

SEPTEMBER 5, 2020

| Añadir a lista de seguimiento Biotech365 : ^^BIORAD 7500502 Signal Importación Módulo Hr – Nuevo BioMarketplace You want to propose your products or a Biotech … Continue reading →

HR 40

HR Production 40

Pharmaceutical Technology

MARCH 6, 2023

Verzenio along with endocrine therapy (ET) has received approval as an adjuvant treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) adult patients who are at a high recurrence risk.

FDA Approval 130

FDA Approval Clinical Trials Clinical Trials Hormones 130

The Pharma Data

MARCH 25, 2021

months with letrozole alone (HR 0.58: 95% CI, 0.49 months among patients in the letrozole group (HR 0.66: 95% CI, 0.53 This real-world cohort includes more than 1,400 women with HR+, HER2- mBC with any extent of visceral disease. months with IBRANCE plus letrozole versus 11.9 to 0.82; P=0.0002). in the IBRANCE group and 68.0%

HR 52

HR Clinical Trials Clinical Trials Trials 52

BioSpace

SEPTEMBER 21, 2023

The companies’ antibody-drug conjugate improved progression-free survival with a “trend in improvement” for overall survival in patients with HR-positive, HER2-low or negative breast cancer.

Antibody 116

Antibody Drugs HR 116

XTalks

NOVEMBER 20, 2023

AstraZeneca has won its first-in-class approval for its AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. billion to $1.28

FDA Approval 98

FDA Approval Gene Drugs Trials 98

Pharmaceutical Technology

JUNE 4, 2023

in the placebo arm (hazard ratio [HR]: 0.58). months in the placebo arm (HR: 0.73). At a median duration of follow-up of 25.2 months, the two-year event-free survival (EFS) was 62.4% in the Keytruda arm, versus 40.6% The median EFS was not reached in the Keytruda arm, and was 17 months in the placebo arm.

FDA Approval 189

FDA Approval Trials HR Drugs 189

The Pharma Data

SEPTEMBER 21, 2020

New data has been unveiled for the combination of Novartis’ Piqray (alpelisib) with AstraZeneca’s Faslodex (fulvestrant) in the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer in patients whose tumours are PIK3CA positive. months compared to 14.8

HR 52

HR Hormones Trials 52

BioTech 365

SEPTEMBER 28, 2021

This HR+/HER2-VE Breast … Continue reading →

HR 40

HR Clinical Trials Clinical Trials Trials 40

BioTech 365

DECEMBER 10, 2021

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i New data underscore efficacy … Continue reading →

HR 40

HR 40

BioTech 365

APRIL 15, 2021

BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada OTTAWA, Ontario–(BUSINESS … Continue reading →

HR 52

HR 52

Scienmag

SEPTEMBER 20, 2020

Data from latest research presented at the ESMO Virtual Congress 2020 Lugano, Switzerland, 20 September 2020 – Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to (..)

Hormones 45

Hormones HR Drugs Research 45

BioTech 365

MARCH 26, 2021

Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer Results from pre-planned subgroup (..)

HR 40

HR 40

Pharmaceutical Technology

SEPTEMBER 26, 2022

The 'life-extending' drug combination is recommended for usage in adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer who have previously received hormone therapy. In addition to palbociclib, NICE has granted approval for 15 other therapies for breast cancer since 2018.

Drugs 130

Drugs Hormones Medicine Protein 130

BioTech 365

DECEMBER 9, 2020

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast … Continue reading →

Trials 52

Trials HR 52

Pharma Mirror

OCTOBER 17, 2022

International biopharma executive Guillaume Herry has been appointed as CEO, while HR executive Joanne Reichardt has been appointed Head of People & Culture. Glenn Haifer and Ampersand Capital Partners, announced today new senior executive hires to support global growth plans.

Protein 130

Protein Vaccination Vaccine HR 130

Pharmaceutical Technology

MARCH 6, 2023

months for the chemotherapy arm (hazard ratio [HR]: 0.52). While the data will be presented at an upcoming meeting, a previous analysis of the two arms for OS showed an HR of 0.59, which could lead to a modest but clinically meaningful improvement in OS. At a median follow-up of 22.1 months, the PFS for the Tuoyi arm was 21.4

FDA Approval 130

FDA Approval Antibody Trials HR 130

BioTech 365

SEPTEMBER 19, 2020

In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to fulvestrant alone1 14+ months OS improvement was achieved in … Continue reading →

HR 40

HR 40

Pharmaceutical Technology

JULY 25, 2022

AstraZeneca noted that the sBLA is based on findings from the randomised, open-label Phase III DESTINY-Breast04 clinical trial of Enhertu in priorly treated subjects with HER2-low metastatic breast cancer with hormone receptor (HR)-positive or HR-negative disease.

Clinical Trials 130

Clinical Trials Clinical Trials Hormones Antibody 130

World of DTC Marketing

JANUARY 14, 2022

One of the people I work with has more than 20 years of experience as an HR VP. Yet, when she was contacted about taking over a small companies HR department, she declined because the hiring process consisted of too many interviews over too long a period. Stories about hiring processes within pharma are more like nightmares.

Pharma Companies 277

Pharma Companies HR Production Marketing 277

Scienmag

JUNE 30, 2021

Credit: NTU Singapore Nanyang Technological University, Singapore (NTU Singapore) is collaborating with the Institute for Human Resource Professionals (IHRP) to launch two new MiniMasters™ programmes to develop talent in human resources (HR).

Development 89

Development HR 89